GlassScriptPhysician profile
Andrew Michael Roth
NPI 1376246538
$2,935.40
in general payments reported to CMS, 2019-2025
19 companies · $2,446 in 2025
The $2,446 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $12.81 · 2024: $477 · 2025: $2,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,746 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.41 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,293.58 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $407.14 | 2025 | Zoryve |
| Ucb, INC. | $305.29 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $149.81 | 2025 | Dupixent, Libtayo |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Janssen Biotech, INC. | $89.99 | 2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $84.76 | 2024-2025 | |
| Amgen INC. | $79.80 | 2024-2025 | Otezla, Otezla |
| Incyte Corporation | $72.54 | 2025 | Opzelura |
| Abbvie INC. | $64.62 | 2025 | |
| Pfizer INC. | $56.49 | 2025 | |
| Laborie Medical Technologies Corp. | $49.21 | 2024 | Goby |
| Ibsa Pharma INC. | $48.34 | 2023-2025 | Tirosint, Licart, Tirosint |
| Lilly USA, LLC | $34.09 | 2025 | Ebglyss |
| Leo Pharma INC. | $27.30 | 2025 | Anzupgo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $22.64 | 2025 | Aklief |
| Dexcom, INC. | $20.94 | 2024 | Dexcom G6 Transmitter |
| Exeltis, USA INC. | $16.71 | 2024 | Slynd |
| Seqirus USA INC | $13.15 | 2024 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.